Schrodinger (NASDAQ:SDGR) Stock: Insider Yvonne Tran Sells 32,000 Shares

Schrodinger, Inc. (NASDAQ:SDGR) EVP Yvonne Tran sold 32,000 shares of Schrodinger stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $32.85, for a total transaction of $1,051,200.00. Following the completion of the sale, the executive vice president owned 52,683 shares of the company’s stock, valued at $1,730,636.55. This trade represents a 37.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Schrodinger Stock Down 2.7%

SDGR stock opened at $31.52 on Thursday. The company has a market capitalization of $2.33 billion, a price-to-earnings ratio of -39.90 and a beta of 1.69. Schrodinger, Inc. has a 12 month low of $10.94 and a 12 month high of $34.00. The firm has a 50 day moving average of $26.55 and a two-hundred day moving average of $17.32.

Schrodinger (NASDAQ:SDGR) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.17. The business had revenue of $64.49 million for the quarter, compared to the consensus estimate of $47.73 million. Schrodinger had a negative net margin of 22.02% and a negative return on equity of 18.12%. Schrodinger’s revenue for the quarter was up 18.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.45) EPS. On average, research analysts expect that Schrodinger, Inc. will post -1.39 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Zacks Research downgraded shares of Schrodinger from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 3rd. BMO Capital Markets boosted their price target on Schrodinger from $24.00 to $30.00 and gave the stock an “outperform” rating in a research report on Monday, October 12th. TD Cowen upped their price target on Schrodinger from $31.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th. Weiss Ratings upgraded Schrodinger from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th. Finally, KeyCorp increased their price objective on Schrodinger from $20.00 to $32.00 and gave the company an “overweight” rating in a report on Friday, October 16th. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Schrodinger has an average rating of “Hold” and an average price target of $26.67.

Institutional Trading of Schrodinger

Institutional investors and hedge funds have recently modified their holdings of the company. Ieq Capital LLC grew its stake in Schrodinger by 29.6% in the 3rd quarter. Ieq Capital LLC now owns 92,553 shares of the company’s stock valued at $2,874,000 after buying an additional 21,156 shares during the last quarter. Focus Advisor Solutions LLC bought a new position in Schrodinger in the 3rd quarter worth $347,000. Stelac Advisory Services LLC bought a new position in Schrodinger in the 3rd quarter worth $102,000. Public Sector Pension Investment Board lifted its position in Schrodinger by 79.0% during the 3rd quarter. Public Sector Pension Investment Board now owns 350,738 shares of the company’s stock worth $10,890,000 after acquiring an additional 154,824 shares during the last quarter. Finally, Edgestream Partners L.P. acquired a new position in Schrodinger during the 3rd quarter worth $5,271,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

About Schrodinger

Schrödinger, Inc. develops computational software used to support drug discovery and materials research. Its platform applies physics-based modeling, computational chemistry and machine learning to help researchers analyze molecular properties and identify promising candidates. The company’s tools are used by pharmaceutical and biotechnology companies, academic institutions and other research organizations. Alongside software sales and subscriptions, Schrödinger works with partners on drug discovery programs and advances a portfolio of its own therapeutic candidates.